{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T18:21:08Z","timestamp":1788114068420,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T00:00:00Z","timestamp":1673654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T00:00:00Z","timestamp":1673654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005971","name":"Deutsche Herzstiftung","doi-asserted-by":"publisher","award":["[F\/19\/18]"],"award-info":[{"award-number":["[F\/19\/18]"]}],"id":[{"id":"10.13039\/501100005971","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Industrially processed trans-fatty acids (IP-TFA) have been linked to altered lipoprotein metabolism, inflammation and increased NT-proBNP. In patients with heart failure with preserved ejection fraction (HFpEF), associations of TFA blood levels with patient characteristics are unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This is a secondary analysis of the Aldo-DHF-RCT. From 422 patients, individual blood TFA were analyzed at baseline in\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009404 using the HS-Omega-3-Index\n                      <jats:sup>\u00ae<\/jats:sup>\n                      methodology. Patient characteristics were: 67\u2009\u00b1\u20098\u00a0years, 53% female, NYHA II\/III (87\/13%), ejection fraction \u2265\u200950%,\n                      <jats:italic>E<\/jats:italic>\n                      \/\n                      <jats:italic>e<\/jats:italic>\n                      \u2032 7.1\u2009\u00b1\u20091.5; NT-proBNP 158\u00a0ng\/L (IQR 82\u2013298). A principal component analysis was conducted but not used for further analysis as cumulative variance for the first two PCs was low. Spearman\u2019s correlation coefficients as well as linear regression analyses, using sex and age as covariates, were used to describe associations of whole blood TFA with metabolic phenotype, functional capacity, echocardiographic markers for LVDF and neurohumoral activation at baseline and after 12\u00a0months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Blood levels of the naturally occurring TFA C16:1n-7t were inversely associated with dyslipidemia, body mass index\/truncal adiposity, surrogate markers for non-alcoholic fatty liver disease and inflammation at baseline\/12\u00a0months. Conversely, IP-TFA C18:1n9t, C18:2n6tt and C18:2n6tc were positively associated with dyslipidemia and isomer C18:2n6ct with dysglycemia. C18:2n6tt and C18:2n6ct were inversely associated with submaximal aerobic capacity at baseline\/12\u00a0months. No significant association was found between TFA and cardiac function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In HFpEF patients, higher blood levels of IP-TFA, but not naturally occurring TFA, were associated with dyslipidemia, dysglycemia and lower functional capacity. Blood TFAs, in particular C16:1n-7t, warrant further investigation as prognostic markers in HFpEF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                    <jats:p>Higher blood levels of industrially processed TFA, but not of the naturally occurring TFA C16:1n-7t, are associated with a higher risk cardiometabolic phenotype and prognostic of lower aerobic capacity in patients with HFpEF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00392-022-02143-7","type":"journal-article","created":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T06:02:38Z","timestamp":1673676158000},"page":"1541-1554","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Trans-fatty acid blood levels of industrial but not natural origin are associated with cardiovascular risk factors in patients with HFpEF: a secondary analysis of the Aldo-DHF trial"],"prefix":"10.1007","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3582-3512","authenticated-orcid":false,"given":"Katharina","family":"Lechner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Bock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"von Schacky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Scherr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Lorenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Lechner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Haller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Krannich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Halle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Wachter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Duvinage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Edelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,14]]},"reference":[{"issue":"4","key":"2143_CR1","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1001\/jama.300.4.431","volume":"300","author":"SJ Shah","year":"2008","unstructured":"Shah SJ, Gheorghiade M (2008) Heart failure with preserved ejection fraction: treat now by treating comorbidities. JAMA 300(4):431\u2013433","journal-title":"JAMA"},{"issue":"20","key":"2143_CR2","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1016\/j.jacc.2018.03.509","volume":"71","author":"M Packer","year":"2018","unstructured":"Packer M (2018) Epicardial adipose tissue may mediate deleterious effects of obesity and inflammation on the myocardium. J Am Coll Cardiol 71(20):2360\u20132372","journal-title":"J Am Coll Cardiol"},{"issue":"40","key":"2143_CR3","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","volume":"40","author":"B Pieske","year":"2019","unstructured":"Pieske B et al (2019) How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J 40(40):3297\u20133317","journal-title":"Eur Heart J"},{"issue":"5","key":"2143_CR4","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/ejhf.1170","volume":"20","author":"PM Seferovi\u0107","year":"2018","unstructured":"Seferovi\u0107 PM et al (2018) Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 20(5):853\u2013872","journal-title":"Eur J Heart Fail"},{"issue":"36","key":"2143_CR5","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA et al (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 42(36):3599\u20133726","journal-title":"Eur Heart J"},{"key":"2143_CR6","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385(16):1451\u20131461","journal-title":"N Engl J Med"},{"issue":"17","key":"2143_CR7","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1016\/j.jacc.2011.06.054","volume":"58","author":"F Edelmann","year":"2011","unstructured":"Edelmann F et al (2011) Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study. J Am Coll Cardiol 58(17):1780\u20131791","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"2143_CR8","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1056\/NEJMra054035","volume":"354","author":"D Mozaffarian","year":"2006","unstructured":"Mozaffarian D et al (2006) Trans fatty acids and cardiovascular disease. N Engl J Med 354(15):1601\u20131613","journal-title":"N Engl J Med"},{"key":"2143_CR9","doi-asserted-by":"publisher","first-page":"e001195","DOI":"10.1161\/JAHA.114.001195","volume":"3","author":"R Chowdhury","year":"2014","unstructured":"Chowdhury R, Johnson L, Steur M (2014) Trans fatty acid isomers in mortality and incident coronary heart disease risk. J Am Heart Assoc 3(4):e001195","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"2143_CR10","doi-asserted-by":"publisher","first-page":"398","DOI":"10.7326\/M13-1788","volume":"160","author":"R Chowdhury","year":"2014","unstructured":"Chowdhury R et al (2014) Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis. Ann Intern Med 160(6):398\u2013406","journal-title":"Ann Intern Med"},{"issue":"Suppl 2","key":"2143_CR11","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1038\/sj.ejcn.1602973","volume":"63","author":"D Mozaffarian","year":"2009","unstructured":"Mozaffarian D, Aro A, Willett WC (2009) Health effects of trans-fatty acids: experimental and observational evidence. Eur J Clin Nutr 63(Suppl 2):S5\u2013S21","journal-title":"Eur J Clin Nutr"},{"issue":"4","key":"2143_CR12","doi-asserted-by":"publisher","first-page":"698","DOI":"10.3945\/ajcn.112.050120","volume":"97","author":"OA Tokede","year":"2013","unstructured":"Tokede OA et al (2013) Plasma phospholipid trans fatty acids and risk of heart failure. Am J Clin Nutr 97(4):698\u2013705","journal-title":"Am J Clin Nutr"},{"issue":"6","key":"2143_CR13","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.ahj.2008.07.014","volume":"156","author":"RC Block","year":"2008","unstructured":"Block RC et al (2008) Omega-6 and trans fatty acids in blood cell membranes: a risk factor for acute coronary syndromes? Am Heart J 156(6):1117\u20131123","journal-title":"Am Heart J"},{"key":"2143_CR14","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.atherosclerosis.2019.02.025","volume":"284","author":"S Koba","year":"2019","unstructured":"Koba S et al (2019) Comparison of plasma levels of different species of trans fatty acids in Japanese male patients with acute coronary syndrome versus healthy men. Atherosclerosis 284:173\u2013180","journal-title":"Atherosclerosis"},{"issue":"2","key":"2143_CR15","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.amjcard.2006.08.013","volume":"99","author":"WS Harris","year":"2007","unstructured":"Harris WS et al (2007) Blood omega-3 and trans fatty acids in middle-aged acute coronary syndrome patients. Am J Cardiol 99(2):154\u2013158","journal-title":"Am J Cardiol"},{"issue":"13","key":"2143_CR16","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/eurheartj\/ehv446","volume":"37","author":"ME Kleber","year":"2016","unstructured":"Kleber ME et al (2016) Trans-fatty acids and mortality in patients referred for coronary angiography: the Ludwigshafen Risk and Cardiovascular Health Study. Eur Heart J 37(13):1072\u20131078","journal-title":"Eur Heart J"},{"issue":"3","key":"2143_CR17","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1017\/S0007114508925435","volume":"100","author":"E Lee","year":"2008","unstructured":"Lee E, Lee S, Park Y (2008) n-3 Polyunsaturated fatty acids and trans fatty acids in patients with the metabolic syndrome: a case\u2013control study in Korea. Br J Nutr 100(3):609\u2013614","journal-title":"Br J Nutr"},{"issue":"4","key":"2143_CR18","doi-asserted-by":"publisher","first-page":"854","DOI":"10.2337\/dc21-1756","volume":"45","author":"HTM Lai","year":"2022","unstructured":"Lai HTM et al (2022) Trans fatty acid biomarkers and incident type 2 diabetes: pooled analysis of 12 prospective cohort studies in the Fatty Acids and Outcomes Research Consortium (FORCE). Diabetes Care 45(4):854\u2013863","journal-title":"Diabetes Care"},{"issue":"6","key":"2143_CR19","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1093\/ajcn\/80.6.1521","volume":"80","author":"D Mozaffarian","year":"2004","unstructured":"Mozaffarian D et al (2004) Trans fatty acids and systemic inflammation in heart failure. Am J Clin Nutr 80(6):1521\u20131525","journal-title":"Am J Clin Nutr"},{"issue":"10","key":"2143_CR20","doi-asserted-by":"publisher","first-page":"e76632","DOI":"10.1371\/journal.pone.0076632","volume":"8","author":"E Archer","year":"2013","unstructured":"Archer E, Hand GA, Blair SN (2013) Validity of U.S. nutritional surveillance: National Health and Nutrition Examination Survey caloric energy intake data, 1971\u20132010. PLoS\u00a0One 8(10):e76632","journal-title":"PLoS\u00a0One"},{"issue":"3","key":"2143_CR21","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1007\/s00392-021-01925-9","volume":"111","author":"K Lechner","year":"2022","unstructured":"Lechner K et al (2022) Omega-3 fatty acid blood levels are inversely associated with cardiometabolic risk factors in HFpEF patients: the Aldo-DHF randomized controlled trial. Clin Res Cardiol 111(3):308\u2013321","journal-title":"Clin Res Cardiol"},{"key":"2143_CR22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jclinepi.2018.08.003","volume":"104","author":"E Archer","year":"2018","unstructured":"Archer E, Marlow ML, Lavie CJ (2018) Controversy and debate: memory-based methods paper 1: the fatal flaws of food frequency questionnaires and other memory-based dietary assessment methods. J Clin Epidemiol 104:113\u2013124","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"2143_CR23","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1161\/01.CIR.0000142292.10048.B2","volume":"110","author":"WS Harris","year":"2004","unstructured":"Harris WS et al (2004) Omega-3 fatty acids in cardiac biopsies from heart transplantation patients: correlation with erythrocytes and response to supplementation. Circulation 110(12):1645\u20131649","journal-title":"Circulation"},{"issue":"8","key":"2143_CR24","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1001\/jama.2013.905","volume":"309","author":"F Edelmann","year":"2013","unstructured":"Edelmann F et al (2013) Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 309(8):781\u2013791","journal-title":"JAMA"},{"issue":"1\u20134","key":"2143_CR25","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.prostaglandins.2011.06.008","volume":"96","author":"C von Schacky","year":"2011","unstructured":"von Schacky C (2011) The Omega-3 Index as a risk factor for cardiovascular diseases. Prostaglandins Other Lipid Mediat 96(1\u20134):94\u201398","journal-title":"Prostaglandins Other Lipid Mediat"},{"issue":"6","key":"2143_CR26","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s11886-010-0141-6","volume":"12","author":"WS Harris","year":"2010","unstructured":"Harris WS (2010) The omega-3 index: clinical utility for therapeutic intervention. Curr Cardiol Rep 12(6):503\u2013508","journal-title":"Curr Cardiol Rep"},{"issue":"9","key":"2143_CR27","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1161\/01.CIR.0000073597.57414.A9","volume":"108","author":"MD Cheitlin","year":"2003","unstructured":"Cheitlin MD et al (2003) ACC\/AHA\/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (ACC\/AHA\/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation 108(9):1146\u20131162","journal-title":"Circulation"},{"issue":"7","key":"2143_CR28","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jacc.2020.05.077","volume":"76","author":"A Astrup","year":"2020","unstructured":"Astrup A et al (2020) Saturated fats and health: a reassessment and proposal for food-based recommendations: JACC state-of-the-art review. J Am Coll Cardiol 76(7):844\u2013857","journal-title":"J Am Coll Cardiol"},{"key":"2143_CR29","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.plefa.2018.11.012","volume":"140","author":"D Berliner","year":"2019","unstructured":"Berliner D et al (2019) The omega-3 index in patients with heart failure: a prospective cohort study. Prostaglandins Leukot Essent Fatty Acids 140:34\u201341","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"issue":"10","key":"2143_CR30","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41569-019-0206-1","volume":"16","author":"JHY Wu","year":"2019","unstructured":"Wu JHY, Micha R, Mozaffarian D (2019) Dietary fats and cardiometabolic disease: mechanisms and effects on risk factors and outcomes. Nat Rev Cardiol 16(10):581\u2013601","journal-title":"Nat Rev Cardiol"},{"issue":"2","key":"2143_CR31","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1161\/CIRCRESAHA.117.309008","volume":"122","author":"D Mozaffarian","year":"2018","unstructured":"Mozaffarian D, Wu JHY (2018) Flavonoids, dairy foods, and cardiovascular and metabolic health: a review of emerging biologic pathways. Circ Res 122(2):369\u2013384","journal-title":"Circ Res"},{"issue":"2","key":"2143_CR32","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3945\/ajcn.112.037770","volume":"96","author":"MC de Oliveira Otto","year":"2012","unstructured":"de Oliveira Otto MC et al (2012) Dietary intake of saturated fat by food source and incident cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis. Am J Clin Nutr 96(2):397\u2013404","journal-title":"Am J Clin Nutr"},{"issue":"24","key":"2143_CR33","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","volume":"41","author":"J Bor\u00e9n","year":"2020","unstructured":"Bor\u00e9n J et al (2020) Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 41(24):2313\u20132330","journal-title":"Eur Heart J"},{"issue":"9","key":"2143_CR34","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1001\/jamacardio.2019.2261","volume":"4","author":"K Lechner","year":"2019","unstructured":"Lechner K, Halle M (2019) Are atherogenic lipoprotein phenotype and inflammation indicative of plaque phenotype and clinical stability in coronary artery disease? JAMA Cardiol 4(9):950\u2013951","journal-title":"JAMA Cardiol"},{"issue":"4","key":"2143_CR35","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1089\/met.2019.0115","volume":"18","author":"K Lechner","year":"2020","unstructured":"Lechner K et al (2020) High-risk atherosclerosis and metabolic phenotype: the roles of ectopic adiposity, atherogenic dyslipidemia, and inflammation. Metab Syndr Relat Disord 18(4):176\u2013185","journal-title":"Metab Syndr Relat Disord"},{"issue":"9","key":"2143_CR36","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1001\/jamacardio.2019.2231","volume":"4","author":"R Vergallo","year":"2019","unstructured":"Vergallo R, Porto I, Crea F (2019) Are atherogenic lipoprotein phenotype and inflammation indicative of plaque phenotype and clinical stability in coronary artery disease?\u2014reply. JAMA Cardiol 4(9):951\u2013952","journal-title":"JAMA Cardiol"},{"issue":"3","key":"2143_CR37","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jacc.2018.04.061","volume":"72","author":"OP Ganda","year":"2018","unstructured":"Ganda OP et al (2018) Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol 72(3):330\u2013343","journal-title":"J Am Coll Cardiol"},{"key":"2143_CR38","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12933-014-0168-x","volume":"14","author":"R Fontes-Carvalho","year":"2015","unstructured":"Fontes-Carvalho R et al (2015) Diastolic dysfunction in the diabetic continuum: association with insulin resistance, metabolic syndrome and type 2 diabetes. Cardiovasc Diabetol 14:4","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"2143_CR39","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.3945\/jn.112.158295","volume":"142","author":"WS Harris","year":"2012","unstructured":"Harris WS et al (2012) Changes in erythrocyte membrane trans and marine fatty acids between 1999 and 2006 in older Americans. J Nutr 142(7):1297\u20131303","journal-title":"J Nutr"},{"key":"2143_CR40","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.nutres.2019.09.010","volume":"71","author":"A Sala-Vila","year":"2019","unstructured":"Sala-Vila A, Jackson KH, Harris WS (2019) Parallel declines in erythrocyte trans fatty acids and US fatal ischemic heart disease rates. Nutr Res 71:111\u2013114","journal-title":"Nutr Res"},{"issue":"4","key":"2143_CR41","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1007\/s00394-016-1218-9","volume":"56","author":"C von Schacky","year":"2017","unstructured":"von Schacky C, Passow A, Kiefl R (2017) Trans-fatty acid levels in erythrocytes in Europe. Eur J Nutr 56(4):1719\u20131723","journal-title":"Eur J Nutr"},{"issue":"4","key":"2143_CR42","doi-asserted-by":"publisher","first-page":"883","DOI":"10.3945\/ajcn.2009.28877","volume":"91","author":"R Micha","year":"2010","unstructured":"Micha R et al (2010) Food sources of individual plasma phospholipid trans fatty acid isomers: the Cardiovascular Health Study. Am J Clin Nutr 91(4):883\u2013893","journal-title":"Am J Clin Nutr"},{"issue":"4","key":"2143_CR43","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1177\/2047487319869400","volume":"27","author":"K Lechner","year":"2020","unstructured":"Lechner K et al (2020) Lifestyle factors and high-risk atherosclerosis: pathways and mechanisms beyond traditional risk factors. Eur J Prev Cardiol 27(4):394\u2013406","journal-title":"Eur J Prev Cardiol"},{"issue":"9","key":"2143_CR44","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.3390\/biomedicines10092296","volume":"10","author":"K Lechner","year":"2022","unstructured":"Lechner K et al (2022) Saturated fatty acid blood levels and cardiometabolic phenotype in patients with HFpEF: a secondary analysis of the Aldo-DHF trial. Biomedicines 10(9):2296","journal-title":"Biomedicines"},{"issue":"40","key":"2143_CR45","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","volume":"40","author":"B Pieske","year":"2019","unstructured":"Pieske B et al (2019) How to diagnose heart failure with preserved ejection fraction: the HFA\u2013PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J 40(40):3297\u20133317","journal-title":"Eur Heart J"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-022-02143-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-022-02143-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-022-02143-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T05:03:03Z","timestamp":1697605383000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-022-02143-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,14]]},"references-count":45,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["2143"],"URL":"https:\/\/doi.org\/10.1007\/s00392-022-02143-7","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,14]]},"assertion":[{"value":"25 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KL, MB, JS, EL, BL, BH, AK, MH, RW, AD and FE declare that they have no conflict of interest to disclose with respect to this manuscript. CvS operates Omegametrix, a laboratory for fatty acid analyses.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}